Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT05849740

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-05

25

Participants Needed

1

Research Sites

231 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA. To evaluate the safety of CD38 monoclonal antibody in the treatment of AHA.

CONDITIONS

Official Title

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with Acquired Hemophilia A (AHA)
  • Women must be postmenopausal or use strict contraception if of childbearing age
  • Patients must have good compliance with study requirements
Not Eligible

You will not qualify if you...

  • Diagnosis of congenital hemophilia with inhibitor
  • Pregnant or lactating women
  • Positive for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, or syphilis antibody
  • Poor compliance with study requirements
  • Inability to use contraception during the trial
  • Patients deemed unsuitable by researchers for any other reason
  • Received immunosuppressive therapy within 4 weeks before enrollment with less than 50% decrease in inhibitor
  • Presence of acquired von Willebrand disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chinese Academy of Medical Science and Blood Disease Hospital

Tianjin, China

Actively Recruiting

Loading map...

Research Team

W

Wei Liu

CONTACT

L

Lei Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here